Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 5, 2013, Pages 442-445

  Ando, Yukie ^a   Shimada, Hideaki ^b   Matsumoto, Nozomi ^a   Hirota, Takeshi ^a   Oribe, Motohiro ^c   Otsuka, Eiji ^c   Ishii, Kohji ^b   Morimoto, Takuya ^b   Ohashi, Kyoichi ^b   Ieiri, Ichiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

^c Oribe Rheumatism and Internal Medicine Clinic   (Japan)

Author keywords

Gene polymorphisms; Methotrexate; MTX polyglutamates; Reduced folate carrier 1 (RFC1)

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; METHOTREXATE;

ADULT; AGED; CELL LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG METABOLISM; DRUG POLYGLUTAMATION; DRUG RESPONSE; ERYTHROCYTE; FEMALE; FOLATE METABOLISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOTE; RFC1 GENE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; VISUAL ANALOG SCALE;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; ERYTHROCYTES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; POLYGLUTAMIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; REDUCED FOLATE CARRIER PROTEIN;

EID: 84886403829     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-128     Document Type: Article

References (19)

1. Stamp, L., Roberts, R., Kennedy, M., Barclay, M., O'Donnell, J. and Chapman, P.: The use of low dose methotrexate in rheumatoid arthritis-are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed. Pharmacother., 60: 678-687 (2006).
2. Urano, W., Taniguchi, A., Yamanaka, H., Tanaka, E., Nakajima, H., Matsuda, Y., Akama, H., Kitamura, Y. and Kamatani, N.: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics, 12: 183-190 (2002).
3. Kremer, J. M., Galivan, J., Streckfuss, A. and Kamen, B.: Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum., 29: 832-835 (1986).
4. Allegra, C. J., Drake, J. C., Jolivet, J. and Chabner, B. A.: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. USA, 82: 4881-4885 (1985).
5. Chabner, B. A., Allegra, C. J., Curt, G. A., Clendeninn, N. J., Baram, J., Koizumi, S., Drake, J. C. and Jolivet, J.: Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest., 76: 907-912 (1985).
6. Dervieux, T., Furst, D., Lein, D. O., Capps, R., Smith, K., Walsh, M. and Kremer, J.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum., 50: 2766-2774 (2004).
7. Angelis-Stoforidis, P., Vajda, F. J. and Christophidis, N.: Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol., 17: 313-320 (1999).
8. Sirotnak, F. M. and Tolner, B.: Carrier-mediated membrane transport of folates in mammalian cells. Annu. Rev. Nutr., 19: 91-122 (1999).
9. Zeng, H., Chen, Z. S., Belinsky, M. G., Rea, P. A. and Kruh, G. D.: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res., 61: 7225-7232 (2001).
10. Chen, Z. S., Robey, R. W., Belinsky, M. G., Shchaveleva, I., Ren, X. Q., Sugimoto, Y., Ross, D. D., Bates, S. E. and Kruh, G. D.: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res., 63: 4048-4054 (2003).
11. Brooks, A. J., Begg, E. J., Zhang, M., Frampton, C. M. and Barclay, M. L.: Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther. Drug Monit., 29: 619-625 (2007).
12. Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., James, J., Frampton, C. and Barclay, M. L.: Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum., 62: 359-368 (2010).
13. Dervieux, T., Zablocki, R. and Kremer, J.: Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology, 49: 2337-2345 (2010) (Oxford).
14. Dalrymple, J. M., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M. and Barclay, M. L.: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum., 58: 3299-3308 (2008).
15. Jolivet, J. and Chabner, B. A.: Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. J. Clin. Invest., 72: 773-778 (1983).
16. Whetstine, J. R., Gifford, A. J., Witt, T., Liu, X. Y., Flatley, R. M., Norris, M., Haber, M., Taub, J. W., Ravindranath, Y. and Matherly, L. H.: Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin. Cancer Res., 7: 3416-3422 (2001).
17. Baslund, B., Gregers, J. and Nielsen, C. H.: Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells. Rheumatology (Oxford), 47: 451-453 (2008).
18. Dervieux, T., Kremer, J., Lein, D. O., Capps, R., Barham, R., Meyer, G., Smith, K., Caldwell, J. and Furst, D. E.: Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics, 14: 733-739 (2004).
19. Masson, E., Relling, M. V., Synold, T. W., Liu, Q., Schuetz, J. D., Sandlund, J. T., Pui, C.-H. and Evans, W. E.: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J. Clin. Invest., 97: 73-80 (1996).